Our products

Tadalafil

CAS No.

171596-29-5

Reference product

CIALIS/ELI LILLY

Polymorphic form

Form A (form I)

Tadalafil

Therapeutic Area

Genito-urinary system & sex hormones

Status

commercial

EU DMF readiness

US DMF readiness

024590

CEP

Other documentation

Japanese DMF
Chinese DMF
Brazilian DMF

Drug description:

Tadalafil is used in a treatment of erectile dysfunction in adult males. In order for tadalafil to be effective, sexual stimulation is required.
Tadalafil is not indicated for use by women. 
It is formulated as film coated tablets for an oral route of administration.

Mechanism of action:

Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the absence of sexual stimulation.

 

Disclaimer
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).
Polpharma’s strategic investment in HPAPI facility
We have launched an investment in a specialized facility
for the R&D and Production of highly active substances
with an OEL value of 10 ng/m3 (OEB 6).

The HP API investment includes separate process
laboratories (PDL), analytical laboratories (ADL)
with the possibility of performing Quality Control
analyses, and a GMP kilo-lab production line with
volume up to 1.5 kg with potential volume increase.

LEARN MORE